The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 800,000
- 试验地点
- 1
- 主要终点
- OCS prescription rates
研究概览
简要总结
The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database.
详细描述
South Korea has a compulsory universal health insurance system for entire Korean population. The number of people who are covered was more than 50 million. The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators have performed many studies regarding asthma in South Korea. In this study, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database.
Primary outcome was the OCS prescription in all patients with asthma. Secondary outcome was OCS prescription according to the asthma severity, age, sex, socioeconomic status and the type of hospital.
Inclusion criteria was 1) Age ≥ 15 years; 2) ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis; 3) use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 15 years;
- •ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis
- •use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).
排除标准
- •Those who are not in the insurance system
结局指标
主要结局
OCS prescription rates
时间窗: 1-year
Analysis the OCS prescription in all patients with asthma
次要结局
- OCS prescription according to sex(1-year)
- OCS prescription according to socioeconomic status(1-year)
- OCS prescription according to the type of hospital(1-year)
- OCS prescription according to the asthma severity(1-year)
- OCS prescription according to age(1-year)
研究者
Joon Young Choi
Clinical assistant professor
Incheon St.Mary's Hospital